Athira Pharma Statistics

Total Valuation

Athira Pharma has a market cap or net worth of $73.59 million. The enterprise value is -$72.88 million.

Market Cap	73.59M
Enterprise Value	-72.88M

Important Dates

The next estimated earnings date is Thursday, May 9, 2024, after market close.

Earnings Date	May 9, 2024
Ex-Dividend Date	n/a

Share Statistics

Athira Pharma has 38.33 million shares outstanding. The number of shares has increased by 0.76% in one year.

Shares Outstanding	38.33M
Shares Change (YoY)	+0.76%
Shares Change (QoQ)	+0.12%
Owned by Insiders (%)	2.27%
Owned by Institutions (%)	61.54%
Float	26.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.57
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.01.

Current Ratio	5.37
Quick Ratio	n/a
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -69.10% and return on invested capital (ROIC) is -95.21%.

Return on Equity (ROE)	-69.10%
Return on Assets (ROA)	-59.90%
Return on Capital (ROIC)	-95.21%
Revenue Per Employee	n/a
Profits Per Employee	-$1.81M
Employee Count	65
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.94% in the last 52 weeks. The beta is 2.78, so Athira Pharma's price volatility has been higher than the market average.

Beta (1Y)	2.78
52-Week Price Change	-30.94%
50-Day Moving Average	2.90
200-Day Moving Average	2.47
Relative Strength Index (RSI)	31.44
Average Volume (30 Days)	354,932

Short Selling Information

The latest short interest is 1.04 million, so 2.72% of the outstanding shares have been sold short.

Short Interest	1.04M
Short Previous Month	1.01M
Short % of Shares Out	2.72%
Short % of Float	3.88%
Short Ratio (days to cover)	2.89

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-125.47M
Pretax Income	-117.67M
Net Income	-117.67M
EBITDA	-116.49M
EBIT	-117.67M
Earnings Per Share (EPS)	-$3.09

Full Income Statement

Balance Sheet

The company has $148.05 million in cash and $1.59 million in debt, giving a net cash position of $146.47 million or $3.82 per share.

Cash & Cash Equivalents	148.05M
Total Debt	1.59M
Net Cash	146.47M
Net Cash Per Share	$3.82
Equity / Book Value	130.19M
Book Value Per Share	3.40
Working Capital	125.89M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$100.75 million and capital expenditures -$304,000, giving a free cash flow of -$101.06 million.

Operating Cash Flow	-100.75M
Capital Expenditures	-304,000
Free Cash Flow	-101.06M
FCF Per Share	-$2.66

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Athira Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.76%
Shareholder Yield	-0.76%
Earnings Yield	-159.91%
FCF Yield	-137.33%

Analyst Forecast

The average price target for Athira Pharma is $12.00, which is 525.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$12.00
Price Target Difference	525.00%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2